King Luther Capital Management Corp Fibrogen Inc Transaction History

King Luther Capital Management Corp

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Aug 12, 2019	SELL	$35.13 - $55.53 $1.23 Million - $1.94 Million	-34,911 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$45.35 - $61.65 $1.58 Million - $2.15 Million	34,911 New	34,911 $1.61 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of King Luther Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on King Luther Capital Management Corp with notifications on news.